First Light Diagnostics Closes $8.25 Million Series A-2 Financing
First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced it has closed an oversubscribed $8.25 million Series A-2 financing. The financing includes new investment partners from Think.Health Ventures, 10x Group, and Beacon Angels, along with numerous new individual investors and continued participation from…
First Light Announces Company Name Change
Chelmsford, MA – January 7, 2019 — First Light Biosciences, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic-resistant infections, today announced that effective immediately, the company is changing their name to First Light Diagnostics. The new name reflects the company’s evolution from development to commercialization of diagnostic solutions….
First Light Diagnostics Announces New Corporate Headquarters in Chelmsford, Massachusetts
New facility offers additional space, state of the art laboratory, added manufacturing capacity Chelmsford, Massachusetts, December 5, 2018 (Newswire.com) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections, today announced its recent move to a new corporate headquarters in Chelmsford,…
First Light Diagnostics Develops Rapid Test for C. Difficile Toxin B. in Stool Samples
Results of Technical Study Presented at ASM Microbe 2018 Chelmsford, MA, November 27, 2018 (Newswire.com) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections, today announced the results of their scientific poster, “A Rapid Single Molecule Counting Method Sensitively Detects Clostridium…
First Light Diagnostics Announces Peer-Reviewed Publication
Describing rapid and accurate immunoassay-based technology capable of counting single molecules using digital imaging without magnification Bedford, Massachusetts, October 25, 2018 (Newswire.com) – Bedford, Massachusetts, October 25, 2018 (Newswire) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections today announced…
First Light Diagnostics Announces Funding from Biomedical Advanced Research and Development Authority (BARDA)
A contract extension representing $10.7 million over 2 years Bedford, MA – (October 11, 2018) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections, announced today that BARDA has approved a $10.7 million extension of the Company’s multi-year contract…
First Light Diagnostics Develops a Novel Method for Rapidly Determining Effective Antibiotics for Treating Infections
Presenting Their Findings in a Scientific Poster Session at IDWeek BEDFORD, Mass., September 27, 2018 (Newswire.com) – First Light Diagnostics (formerly First Light Biosciences), a provider of innovative diagnostic tests for fighting life-threatening infections and combating the spread of antibiotic resistance, today announced they will be presenting a scientific poster detailing their novel MultiPath™ technology for…
First Light Diagnostics Appoints New CEO and Board Member
Bedford, Massachusetts, August 7, 2018 – First Light Diagnostics (formerly First Light Biosciences), a provider of innovative diagnostic tests for fighting life-threatening infections and combating the spread of antibiotic resistance, today announced the appointment of industry veteran David Macdonald as President, Chief Executive Officer and Board Member. As the new CEO of First Light Diagnostics,…
Updated IDSA/SHEA Clinical Practice Guidelines for Clostridium difficile Infection Recognizes the Importance of Toxin Testing.
The updated Clinical Practice Guidelines for Clostridium difficile from The Infectious Disease Society of America (IDSA) and the Society of Healthcare Epidemiology of America (SHEA) have been recently published in the journal Clinical Infectious Diseases. The new recommendations emphasize the importance of toxin tests in accurately identifying Clostridium difficile infection (CDI) and suggest that this type of testing is…
New Additions to First Light Management Team and Board of Directors
BEDFORD, Mass., November 2, 2017 – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAIs) announced today two new additions to the First Light team. William Moffitt joins the First Light Diagnostics board of directors as its chairman. Mr….